Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreements - Additional Information (Detail)

v3.21.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2020
Mar. 31, 2021
Dec. 31, 2020
License Collaboration And Manufacturing Agreements [Line Items]      
Deferred revenue $ 33,455,000 $ 35,497,000 $ 33,455,000
Deferred revenue 27,795,000 31,811,000 27,795,000
Bayer License Agreement      
License Collaboration And Manufacturing Agreements [Line Items]      
Upfront cash payment received 45,000,000.0    
Additional reimbursement payment for research and process development 15,000,000.0    
Additional upfront cash payment entitle to receive for translational activities, invoiced amount $ 1,300,000   1,300,000
Royalty eligible to receive term after first commercial sale 12 years    
Determined upfront payment for license in order to evaluate transaction price $ 45,000,000.0    
Determined research and process development activities in order to evaluate transaction price 15,000,000.0    
Determined additional specified translational activities in order to evaluate transaction price 5,000,000.0    
Determined fee constituted entire consideration included in transaction price   13,100,000  
Deferred revenue   67,300,000  
Development or sales-based milestone payments received   0  
Bayer License Agreement | Current Liabilities      
License Collaboration And Manufacturing Agreements [Line Items]      
Deferred revenue   35,500,000  
Bayer License Agreement | Long-Term Liabilities      
License Collaboration And Manufacturing Agreements [Line Items]      
Deferred revenue   $ 31,800,000  
Bayer License Agreement | Maximum      
License Collaboration And Manufacturing Agreements [Line Items]      
Additional upfront cash payment entitle to receive for translational activities 5,000,000.0   5,000,000.0
Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones 610,000,000.0   610,000,000.0
Bayer Tech Transfer Agreement      
License Collaboration And Manufacturing Agreements [Line Items]      
License agreement percentage   20.00%  
License agreement amount   $ 3,100,000  
License agreement total fee   $ 15,300,000  
Technology transfer agreements fee remainder   The remainder of the fee will be billed as follows: (i) 40 percent on January 1, 2022, (ii) 20 percent on January 1, 2023 and (iii) 20 percent upon the technology transfer completion  
Transaction fee price   $ 15,300,000  
Bayer Manufacturing Agreement      
License Collaboration And Manufacturing Agreements [Line Items]      
License agreement percentage   50.00%  
Written acceptance of binding purchase order percentage   50.00%  
Bayer Manufacturing Agreement | Maximum      
License Collaboration And Manufacturing Agreements [Line Items]      
Manufacturing services   $ 13,100,000  
Bayer Manufacturing Agreement | Minimum      
License Collaboration And Manufacturing Agreements [Line Items]      
Manufacturing services   6,600,000  
Bayer License Agreement, Bayer Tech Transfer Agreement and Bayer Manufacturing Agreement      
License Collaboration And Manufacturing Agreements [Line Items]      
Revenue   3,600,000 0
Deferred revenue $ 61,300,000 $ 67,300,000 $ 61,300,000